ASSETS
|
|
|
|
|
|
Current assets:
|
|
|
|
Cash and cash equivalents
|
$
|
367,183
|
|
Accounts receivable
|
|
1,943,559
|
|
Prepaid expenses
|
|
105,518
|
|
|
|
|
|
Total current assets
|
|
2,416,260
|
|
|
|
|
|
N ote receivable (Note 4)
|
|
449,976
|
|
Property and equipment, net
|
|
85,019
|
|
Intangible Asset - customer list, net
|
|
308,944
|
|
D eferred finance fees, net
|
|
26,462
|
|
G oodwill
|
|
1,821,495
|
|
O ther assets, net
|
|
19,245
|
|
|
|
|
|
|
$
|
5,127,401
|
|
|
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
|
Current liabilities:
|
|
|
|
Accounts payable and accrued liabilities
|
$
|
890,660
|
|
Accrued interest
|
|
543,795
|
|
O ther liabilities
|
|
212,753
|
|
D ebt settlement
|
|
130,000
|
|
Current portion of obligations under
capital lease
|
|
21,541
|
|
N otes payable
|
|
|
|
Related parties
|
|
967,976
|
|
O thers
|
|
135,000
|
|
|
|
|
|
Total current liabilities
|
|
2,901,725
|
|
|
|
|
|
Convertible notes (N ote 5)
|
|
2,605,385
|
|
O bligations under capital lease
|
|
40,739
|
|
|
|
|
|
|
|
5,547,849
|
|
|
|
|
|
Stockholders' deficit (N otes 5, 6, 7 and 10)
|
|
|
|
Preferred stock; no par value; 1,000,000,000 shares authorized
|
|
-
|
|
Common stock; no par value; 40,000,000,000
shares
|
|
|
|
authorized; 62,851,475 shares issued and outstanding
|
|
24,968,045
|
|
D eferred compensation costs
|
|
(14,000
|
)
|
Common stock to be issued; 2,110,655 shares
|
|
3,272
|
|
Accumulated deficit
|
|
(25,377,765
|
)
|
|
|
|
|
Total stockholders' deficit
|
|
(420,448
|
)
|
|
|
|
|
|
$
|
5,127,401
|
|
The accompanying notes are an integral part of these condensed
consolidated financial statements
3
BANYAN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)
(Expressed in US Dollars)
|
|
Three months ended September 30,
|
|
|
Nine months ended September 30,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from franchised clinics
|
$
|
144,037
|
|
$
|
126,541
|
|
$
|
403,850
|
|
$
|
583,100
|
|
Revenue from diagnostic business
|
|
1,024,363
|
|
|
1,305,663
|
|
|
3,558,536
|
|
|
3,508,414
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,168,400
|
|
|
1,432,204
|
|
|
3,962,386
|
|
|
4,091,514
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
|
|
|
|
|
|
|
|
|
|
expenses
|
|
1,518,030
|
|
|
1,214,349
|
|
|
5,022,890
|
|
|
4,560,209
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations
|
|
(349,630
|
)
|
|
217,855
|
|
|
(1,060,504
|
)
|
|
(468,695
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Management compensation
|
|
(102,000
|
)
|
|
(112,500
|
)
|
|
(875,669
|
)
|
|
(633,000
|
)
|
Finance charge
|
|
(228,062
|
)
|
|
-
|
|
|
(238,571
|
)
|
|
-
|
|
Amortization expense
|
|
(20,359
|
)
|
|
(20,904
|
)
|
|
(60,073
|
)
|
|
(58,192
|
)
|
Debt increase (N ote 9)
|
|
-
|
|
|
-
|
|
|
(230,619
|
)
|
|
-
|
|
Interest income
|
|
2,997
|
|
|
10,349
|
|
|
21,544
|
|
|
30,454
|
|
Interest expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
Related parties
|
|
(6,795
|
)
|
|
(2,861
|
)
|
|
(17,482
|
)
|
|
(10,291
|
)
|
Other
|
|
(529,064
|
)
|
|
(657,466
|
)
|
|
(2,082,424
|
)
|
|
(1,612,029
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
$
|
(1,232,913
|
)
|
$
|
(565,527
|
)
|
$
|
(4,543,798
|
)
|
$
|
(2,751,753
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
$
|
(0.02
|
)
|
$
|
(0.20
|
)
|
$
|
(0.15
|
)
|
$
|
(1.19
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
W eighted average number of
|
|
|
|
|
|
|
|
|
|
|
|
|
common
shares- outstanding -
|
|
|
|
|
|
|
|
|
|
|
|
|
basic
and diluted
|
|
*50,360,008
|
|
|
2,882,091
|
|
|
30,812,792
|
|
|
2,319,400
|
|
* After giving retroactive effect to a 100 for 1 reverse stock
split on September 4, 2007
The accompanying notes are an integral part of these condensed
consolidated financial statements
4
BANYAN CORPORATION
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT
NINE MONTHS ENDED SEPTEMBER 30, 2007
(UNAUDITED)
(Expressed in US Dollars)
|
|
|
|
|
|
|
|
|
|
|
Common
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
stock
|
|
|
|
|
|
Stock-
|
|
|
|
Common stock
|
|
|
Deferred
|
|
|
to be
|
|
|
Accumulated
|
|
|
holders'
|
|
|
|
Shares
|
|
|
Amount
|
|
|
compensation
|
|
|
issued
|
|
|
deficit
|
|
|
deficit
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at January 1, 2007
|
|
9,359,963
|
|
$
|
21,652,765
|
|
$
|
(25,300
|
)
|
$
|
-
|
|
$
|
(20,833,967
|
)
|
$
|
793,498
|
|
Issuance of common stock for services (Notes 6 and 7)
|
|
31,616,667
|
|
|
909,000
|
|
|
|
|
|
|
|
|
|
|
|
909,000
|
|
Stock compensation plans
|
|
|
|
|
-
|
|
|
11,300
|
|
|
|
|
|
|
|
|
11,300
|
|
Conversion of convertible notes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(net of finance fees $14,163)
(Notes 5 and 6)
|
|
40,485,500
|
|
|
1,254,552
|
|
|
|
|
|
|
|
|
|
|
|
1,254,552
|
|
Stock redeemed (Notes 6 and 7)
|
|
(16,500,000
|
)
|
|
(495,000
|
)
|
|
|
|
|
|
|
|
|
|
|
(495,000
|
)
|
Stock to be issued
|
|
(2,110,655
|
)
|
|
(3,272
|
)
|
|
|
|
|
3,272
|
|
|
|
|
|
-
|
|
Beneficial conversion (Note 5)
|
|
|
|
|
1,579,165
|
|
|
|
|
|
|
|
|
|
|
|
1,579,165
|
|
Warrants issued with convertible notes (Note
5)
|
|
|
|
|
70,835
|
|
|
|
|
|
|
|
|
|
|
|
70,835
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4,543,798
|
)
|
|
(4,543,798
|
)
|
Balances at September 30, 2007
|
|
62,851,475
|
|
$
|
24,968,045
|
|
$
|
(14,000
|
)
|
$
|
3,272
|
|
$
|
(25,377,765
|
)
|
$
|
(420,448
|
)
|
* After giving retroactive effect to a 100 for 1 reverse stock
split on September 4, 2007
The accompanying notes are an integral part of these condensed
consolidated financial statements
5
BANYAN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)
(Expressed in US Dollars)
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities of continuing
operations
|
$
|
(1,549,704
|
)
|
$
|
(247,987
|
)
|
|
|
|
|
|
|
|
Cash flows from (used) in investing activities:
|
|
|
|
|
|
|
Business acquisition
|
|
-
|
|
|
(1,821,316
|
)
|
Proceeds on note receivable
|
|
278,407
|
|
|
49,827
|
|
Purchase of property and equipment
|
|
(25,764
|
)
|
|
(4,344
|
)
|
Acquisition of other assets
|
|
-
|
|
|
(9,600
|
)
|
|
|
|
|
|
|
|
|
|
252,643
|
|
|
(1,785,433
|
)
|
|
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
|
|
|
Net proceeds from notes payable, related parties
|
|
(90,000
|
)
|
|
110,184
|
|
Proceeds from convertible notes
|
|
1,650,000
|
|
|
2,850,000
|
|
Payments on long term debt and notes payable
|
|
(26,028
|
)
|
|
(834,892
|
)
|
Proceeds from issuance of common stock
and exercise
|
|
|
|
|
|
|
of options and warrants
|
|
-
|
|
|
18,214
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities of continuing operations
|
|
1,533,972
|
|
|
2,143,506
|
|
|
|
|
|
|
|
|
Net increase in cash
|
|
236,911
|
|
|
110,086
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, beginning of year
|
|
130,272
|
|
|
2,206
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, September 30,
|
$
|
367,183
|
|
$
|
112,292
|
|
The accompanying notes are an integral part of these condensed
consolidated financial statements
6
BANYAN CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)
(Expressed in US Dollars)
1.
|
Basis of presentation
|
|
|
|
The condensed financial statements included herein have
been prepared by the Company, without audit, pursuant to the rules and
regulations of the Securities and Exchange Commission (the SEC).
Certain information and footnote disclosures normally included in financial
statements have been condensed or omitted pursuant to such rules and regulations,
although the Company believes that the disclosures are adequate to make
the information presented not misleading. These condensed financial statements
should be read in conjunction with the annual audited financial statements
and the notes thereto included in the Companys Form 10-KSB Annual
Report and other reports filed with the SEC.
|
|
|
|
The accompanying unaudited interim financial statements
reflect all adjustments of a normal and recurring nature, which are, in
the opinion of management, necessary to present fairly the financial position,
results of operations and cash flows of the Company for the interim periods
presented. The results of operations for these periods are not necessarily
comparable to, or indicative of, results any other interim period or for
the fiscal year taken as whole.
|
|
|
2.
|
Organization, principles of consolidation, going
concern, results of operations and managements plans:
Organization and principles of consolidation:
|
|
|
|
Banyan Corporation (the Company), an Oregon
corporation, was incorporated on June 13, 1978. The Company operates in
two segments of the health care industry: diagnostic imaging and franchising
Chiropractic USA chiropractic clinics. All clinics are operated by independent
entrepreneurs under the terms of franchise arrangements (franchisees).
|
|
|
|
The condensed consolidated financial statements include
the accounts of Banyan Corporation, its wholly- owned subsidiaries, Diagnostic
USA, Inc., Banyan Financial Services, Inc., Franchise Support Network,
Inc., Premier Medical Group, Inc., Atlas Medical Group, Century Neurological.
Inc., Comprehensive Medical, Neurological Medical Associates of N.J, LLC,
Neurological Consultants, LLC, Neurological Services, Inc., Optimal Medical
Group, LLC, Premier Health Services, LLC, Premier Imaging, LLC, Premier
Professional Services, LLC, Providers Medical Group, LLC, Prism Diagnostics,
Inc., West Center Medical Group, Inc., Premier SD, LLC and Virtual Medical
Systems, LLC, its majority-owned (99%) subsidiaries Premier Integra Services,
LLC and Premier National, LLC and its majority-owned (90%) subsidiary,
Chiropractic USA, Inc. and the accounts of Southern Diagnostics, Inc.
in accordance with guidelines established under Emerging Issue Task Force
97-2
Application of FASB Statement No. 94 and APB Opinion 16 to Physician
Practice Management Entities and Certain Other Entities with Contractual
Management Arrangements.
The Company meets all six of the requirements
for a controlling financial interest that results in the consolidation
of Southern Diagnostics, Inc. All significant intercompany accounts and
transactions have been eliminated in consolidation. Banyan Financial Services,
Inc., Franchise Support Network Inc. and Diagnostic USA, Inc. have not
commenced operations. Losses attributable to the minority interest in
Chiropractic USA, Inc. have been consolidated into the Company.
|
7
BANYAN CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)
(Expressed in US Dollars)
2.
|
Organization, principles of consolidation, going
concern, results of operations and managements plans (continued):
Going concern, results of operations and managements
plans:
|
|
|
|
The Company has incurred operating losses for several
years. These losses have caused the Company to operate with limited liquidity
and have created an accumulated deficit and working capital deficiencies
of $25,377,765 and $485,465, respectively, as of September 30, 2007. These
conditions raise substantial doubt about the Companys ability to
continue as a going concern. Managements plans to address these
concerns include the conversion of outstanding debt to equity, additional
equity financing, sales of franchises and increasing collections of receivables
from franchisees and developing the diagnostic imaging business.
|
|
|
|
The accompanying financial statements do not include
any adjustments relating to the recoverability and classification of assets
or the amounts of liabilities that might be necessary should the Company
be unsuccessful in implementing these plans, or otherwise be unable to
continue as a going concern.
|
|
|
3.
|
Summary of significant accounting policies:
Revenue recognition:
|
|
|
|
Fees from franchised clinics include initial franchise
fees and continuing franchise and marketing fees. Initial fees are recognized
as revenue on the opening of a clinic when the Company has performed substantially
all initial services required by the franchise arrangement. Continuing
fees for franchise and marketing are recognized as revenue based on a
percentage of cash collected.
|
|
|
|
Revenue from diagnostic imaging services is calculated
on an overall percentage of what can be expected to be collected from
all outstanding gross billings based on the last five years of billing
history. Gross billings are discounted principally due to the fact that
levels of coverage by the insurance companies for patients vary from policy
to policy and from insurance company to insurance company. This estimate
is reviewed periodically, and, as adjustments become necessary, they are
reported in earnings in the period in which they become known.
|
|
|
|
Net loss per share:
|
|
|
|
Basic net loss per share is computed by dividing the
net loss applicable to common stockholders by the weighted-average number
of shares of common stock outstanding for the year. Diluted net loss per
share reflects the potential dilution that could occur if dilutive securities
were exercised or converted into common stock or resulted in the issuance
of common stock that then shared in the earnings of the Company, unless
the effect of such inclusion would reduce a loss or increase earnings
per share. For the nine months ended September 30, 2007 and 2006, the
effect of the inclusion of dilutive shares would have resulted in a decrease
in loss per share. Accordingly, the weighted average shares outstanding
have not been adjusted for dilutive shares.
|
8
BANYAN CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)
(Expressed in US Dollars)
4.
|
Note receivable:
|
|
|
|
During the period, the Company entered into a new agreement
on its note receivable. Under the agreement, the Company received $244,000
as a partial payment of the note. Furthermore, the borrower now has no
obligation to make monthly payments, no interest will accrue and no royalty
fees will be payable for the following 24 months. At the end of the 24
months the borrower has the option to pay the remaining balance discounted
by $100,000. In the event the balance is not paid after 24 months, then
the discount will not apply, interest will accrue and the obligation to
make royalty payments will commence. The resulting discount is being amortized
over the 24 month interest free period.
|
|
|
5.
|
Convertible notes:
|
|
Face value of notes
|
$
|
5,865,923
|
|
|
Less: unamortized discount
|
|
(3,260,538
|
)
|
|
|
|
|
|
|
|
$
|
2,605,385
|
|
The Company entered into six Securities
Purchase Agreements during the period ended September 30, 2007. Under the agreements,
the Company agreed to sell a total of $1,650,000 in callable secured convertible
notes due between January 19, 2010 and September 26, 2010 with 8% annual interest
payable quarterly. The notes are convertible into shares of the Companys
common stock at the holders option. The conversion price will be equal
to the lesser of $0.57 and the average of the lowest three intra-day trading
prices during the twenty trading days prior to the conversion date discounted
by 50%. Attached to the notes, lenders received 600,000 warrants to purchase
one share of the Companys common stock per warrant. Warrants have a seven-year
term from the date of issuance with an exercise price of $0.10 per share.
As a result of the advances of the amount
$1,650,000 on account of the convertible notes, a beneficial conversion in the
amount of $1,579,165 has been deducted from the face value of the notes and
is amortized over the three-year term of the notes as interest expense. The
warrants are valued at $70,835 based on the Black-Scholes option-pricing model
with the following assumptions: Dividend yield (Nil); expected volatility ranging
from 226% to 254%; risk free interest of 4.75%; and expected term of 7 years.
During the period, $421,016 of the 2004
note (including interest in the amount of $60,949) was converted into 28,731,405
common shares. During the period, $847,699 of the 2006 note (including interest
in the amount of $153,622) was converted into 11,754,095 common shares. Unamortized
finance fees in the amount of $14,163 were deducted from the face value of the
notes converted.
9
BANYAN CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)
(Expressed in US Dollars)
6.
|
Stockholders equity: Preferred stock:
|
|
|
|
The Company has 1,000,000,000 shares of no par value
preferred stock authorized. As of September 30, 2007, none were issued
and outstanding.
|
|
|
|
Common stock:
|
|
|
|
On September 4, 2007, the Companys articles of
incorporation were amended to increase its authorized capital stock from
5,000,000,000 to 40,000,000,000 shares of common stock. In addition, the
Company undergoes a one for one hundred reverse stock split. All shares
and per share amounts presented herein have been adjusted retroactively
to reflect the reverse stock split.
|
|
|
|
The Company has 40,000,000,000 shares of no par value
common stock authorized. As of September 30, 2007, there were 62,851,475
shares issued and outstanding. The Company had 487,000 outstanding options,
1,409,213 outstanding warrants, 2,110,655 shares to be issued for conversion
notice received before September 30, 2007 and a commitment to issue 16,500,000
shares to its chief executive officer and its president and chief financial
officer (see Note 7).
|
|
|
|
Stock transactions:
|
|
|
|
During the period ended September 30, 2007, the Company
issued 40,485,500 shares as a result of conversion of convertible notes
(see Note 5).
|
|
|
|
During the period ended September 30, 2007, the Company
issued 31,616,667 shares for services, valued at $909,000, which was equal
to the market price on the date of issue.
|
|
|
|
During the period ended September 30, 2007, the Company
redeemed 16,500,000 shares from its chief executive officer and its president
and chief financial officer. The shares were valued at $495,000 and recorded
as payable.
|
|
|
|
Stock Options:
|
|
|
|
During the period ended September 30, 2007, 35,450 options
expired and 7,400 were cancelled.
|
|
|
7.
|
Related party transactions:
|
|
|
|
The Company retains the law partnership of its chief
executive officer and its president and chief financial officer, Britannia
Law Firm, to serve as its general counsel and special Canadian counsel.
The Company pays Britannia a monthly retainer of $15,000.
|
|
|
|
During the period ended September 30, 2007, the Company
issued to its chief executive officer and its president and chief financial
officer 16,500,000 shares (8,250,000 each) to bonuses of $39,152 that
were included in accounts payable as at January 1, 2007 and $455,848 for
signing personally several guaranty and pledge agreements since 2004 with
respect to the convertible notes (see note 5). These shares were later
cancelled and treated as treasury stock available for future issuance
and been reissued after the period (see Note 10).
|
|
|
|
As of September 30, 2007, $476,410 included in accounts
payable is due to the Companys chief executive officer, president
and chief financial officer and Britannia Law Firm as compensation expense
and services rendered by Britannia Law Firm. Included in the accounts
payable is the $495,000 that is to be repaid by the issuance of 16,500,000
shares.
|
10
BANYAN CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)
(Expressed in US Dollars)
8.
|
Segment results:
|
|
|
|
The Company operates in two business segments: franchising
chiropractic clinics and diagnostic testing. The accounting policies of
the segments are the same as those described in the summary of significant
accounting policies (see Note 3). The Company evaluates performance based
on operating earnings of the respective business units.
|
|
|
|
During the nine months ended September 30, 2007 and
2006, the segment results are as follows:
|
|
|
|
2007
|
|
|
|
|
Chiropractic
|
|
|
Diagnostic
|
|
|
|
|
|
Consolidated
|
|
|
|
|
franchising
|
|
|
testing
|
|
|
Corporate
|
|
|
total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
$
|
403,850
|
|
$
|
3,558,536
|
|
$
|
-
|
|
$
|
3,962,386
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment operating income (loss)
|
|
62,774
|
|
|
87,185
|
|
|
(1,210,463
|
)
|
|
(1,060,504
|
)
|
|
|
|
2006
|
|
|
|
|
Chiropractic
|
|
|
Diagnostic
|
|
|
|
|
|
Consolidated
|
|
|
|
|
franchising
|
|
|
testing
|
|
|
Corporate
|
|
|
total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
$
|
583,100
|
|
$
|
3,508,414
|
|
$
|
-
|
|
$
|
4,091,514
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment operating income (loss)
|
|
264,022
|
|
|
242,442
|
|
|
(975,159
|
)
|
|
(468,695
|
)
|
|
In March 2007, the Company entered into an addendum
to reduce the amount owed on the acquisition of Premier. Under the terms
of the addendum, the Company agreed to pay a lump sum of $250,000 in April
2007. The payment was not made because of a shortage of working capital.
The Company has renegotiated the addendum and restored the agreement to
its original state. Accordingly, $230,619 has been expensed during the
nine-month period ending September 30, 2007.
|
|
|
10.
|
Subsequent event:
|
|
|
|
In November 2007, the Company reissued 16,500,000 shares
to its chief executive officer and president and chief financial officer
of the Company as repayment (see Note 7).
|
|
|
|
After September 30, 2007, the Company issued 12,545,140
shares upon the conversion of $16,999 in 2004 note interest.
|
|
|
11.
|
Comparative figures
|
|
|
|
Certain of the prior periods comparative figures
have been reclassified to conform to the current periods presentation.
|
11
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS.
Plan of Operation for 2007
Our
operating activities have not yet generated a positive cash flow. We expect
that they will generate a positive cash flow by the end of 2007 and that our
recently acquired diagnostic testing business will generate a positive cash
flow.
In
the fourth quarter of 2006, we entered into an agreement that has to date provided
$2,560,000 from the sale of convertible notes to an investment group. Early
in 2006, we entered into an agreement that provided $3,000,000 from the sale
of convertible notes to an investment group. The proceeds were used to acquire
our diagnostic testing business and as working capital for operating expenses
and accounts payable. In 2004 and 2005, we were provided $3,000,000 from the
sale of convertible notes to this investment group, $1,200,000 in 2004 and $1,800,000
in 2005.
As of
November 7, 2007, the investment group has converted to stock $1,200,000 of
the notes issued in 2004, $800,000 of the notes issued in 2005, and $694,077
of the notes issued in 2006. The aggregate outstanding principal amount of the
remaining convertible notes was $5,865,923 as of that date. We believe without
assurance that the investment group will continue to convert the rest of the
notes to stock. However, the rate of conversion has slowed as a result of the
decrease in our stock price, to which the rate of conversion is tied. It is
not likely that all of the remaining debt will be converted when the remaining
convertible notes begin to come due December 31, 2008. We intend to refinance,
extend or otherwise restructure this debt before it becomes due. In the event
we are unable to do so, we may have to file for protection under the federal
bankruptcy laws and we may be unable to continue in operation as a going concern.
Initially,
revenue improved with the advent of our diagnostic testing business to supplement
our franchise business. However, it is likely that additional liquidity and
capital resources will be necessary to defray our ongoing expenses that have
risen significantly, while revenue decreased slightly in third the quarter and
for the year to date.
In
2005 we formed a joint venture with a diagnostic testing business and acquired
the stock and customer base of another diagnostic testing business from the
owners for $700,000 that we transferred to our joint venture. During the first
quarter of 2006, we acquired all of the diagnostic testing business that is
now operated as a wholly owned subsidiary. The acquisition has increased the
number of employees by
approximately 40. Since then our diagnostic testing
business expanded again through acquisition of the customer base of two additional
diagnostic testing businesses.
In
conjunction with the acquisition of the diagnostic testing business in the first
quarter of 2006, we acquired manufacturing and marketing rights to a new diagnostic
testing device that has FDA pre-marketing approval. Sales of the testing device
have not contributed as expected to our revenue and profitability. Changes in
Medicare and Medicaid pre-approval and reimbursement procedures have caused
sales to decline in 2007. The Company is beginning to re-design its testing
protocol in response to these changes in an effort to regain sales. During the
latter half of 2006, the first period in which we had revenue from sales of
our new device, there were more than sixty sales for revenue of $353,827. During
the first nine months of 2007, there were twenty-eight sales for revenue of
$160,545.
We
have forty-three franchised locations, a decrease of forty percent from last
year as a result of the conclusion or our arrangement with Team WLP and the
loss of its endorsement. One new location has been added in 2007.
Effective
December 31, 2004 we disposed of the former Company-owned chiropractic clinics
in Louisiana. Under deferred payment terms of a note issued by the purchaser,
we received $244,000 in 2007 and $358,438 will be due in 2009.
Our
plan of operation for the remainder of fiscal 2007 is as follows:
12
To
make an effort at establishing positive momentum in the diagnostic testing business
that has generated a positive, although declining, cash flow since we acquired
it; and,
To
obtain additional debt and equity financing to fund our working capital deficiency.
To
date our operations have not been self-sustaining. Our independent registered
public accounting firm issued a report to the effect that certain conditions
raise substantial doubt about our ability to continue as a going concern because
we incurred net losses during 2006 and had a working capital deficiency at year
end. We continue to have net losses. Should we be unable to implement our plan
of operation, our expansion plans may be curtailed, and we may not be able to
continue in operation.
Financial condition at September 30, 2006 and 2007
September
30, 2007
. Stockholders’ deficit was $420,448 and we had a working
capital deficiency of $485,465. Principal sources of liquidity in 2007 included
net proceeds of $1,650,000 from the sale of convertible notes and $3,962,386
in revenue from operations.
September
30, 2006.
Stockholders equity was $618,367 and working capital deficiency
was $2,425,428. Principal sources of liquidity in 2006 included the sale of
$2,915,000 in convertible notes and $4,091,514 in revenue from operations.
Results of operation Nine Months Ended September 30,
2006 and 2007
Loss
from operations increased to $1,060,504 in 2007 from $468,695 in 2006.
Revenue
decreased to $3,962,386 in 2007 from $4,091,514 in 2006. Revenue from the diagnostic
testing business increased $50,122, more than offset by a $179,250 decline in
revenue from franchised operations as a result of franchise terminations, and
decreased collections from franchisees.
Selling,
general and administrative expenses increased to $5,022,890 in 2007 from $4,560,209
in 2006 mainly as a result of an increase in expenses related to the diagnostic
testing business and investor relations expenses incurred in 2007. Other expenses
also increased, including an increase in management compensation from $633,000
in 2006 to $875,669 in 2007 as a result of stock issued to management valued
at $495,000.
We
also incurred interest expense of $2,099,906 mainly from the issuance of additional
convertible notes and the conversion of convertible notes. This represents an
increase from $1,622,320 in 2006. Giving effect to interest expense, overall
net loss increased from $2,751,753 in 2006 to $4,543,798 in 2007.
Results of operation Three Months Ended September 30,
2006 and 2007
Loss
from operations increased to $349,630 in 2007 from income of $217,855 in 2006
as a result of decreased revenue and increases in selling, general and administrative
expenses.
Revenue
decreased to $1,168,400 in 2007 from $1,432,204 in 2006. A decrease in revenue
from the diagnostic testing business of $281,300 accounted for most of the decrease.
Selling,
general and administrative expenses increased to $1,518,030 in 2007 from $1,214,349
in 2006. Other expenses also increased. Interest expense decreased from $660,327
to $535,859. Interest expense resulted mainly from the issuance of additional
convertible notes and the conversion of convertible notes.
Overall
net loss increased from $565,527 in 2006 to $1,232,913 in 2007 as a result of
the increase in loss from operations.
13